Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Real-world study shows injectable GLP-1 drugs for obesity have lower weight loss due to treatment discontinuation.

Eli Lilly & Co. sees 60% sales increase for weight-loss drug in India, tapping into growing demand for anti-obesity solutions ...

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...